EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High burden of clonal mast cell disorders and hereditary α‐tryptasemia in patients who need Hymenoptera venom immunotherapy

Peter Korošec iD, Gunter J Sturm iD, Jonathan J Lyons, Tinkara Pirc Marolt, Manca Svetina, Mitja Košnik iD, Mihaela Zidarn, Mark Kačar, Nina Frelih, Nika Lalek, Ajda Demšar Luzar, Samo Zver und 13 weitere

Allergy · 2024

DOI: 10.1111/all.16084 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy, 2024. Verfasst von Peter Korošec und 24 weiteren Autor:innen. Beteiligte Einrichtung: University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia. Hauptthemen laut MEDLINE: Arthropod Venoms, Tryptases, Hymenoptera, Desensitization, Immunologic. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Javna Agencija za Raziskovalno Dejavnost RS, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, Austrian Science Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In patients who require venom immunotherapy (VIT), there is a need to identify underlying mast cell (MC) disorders since these may affect the risk and severity of future sting reactions and the long‐term effectiveness of VIT.

Methods

1319 individuals with Hymenoptera venom allergy (HVA) who needed VIT from referral centers in Slovenia, Austria, Croatia, and Poland underwent examination for KIT p.D816V in peripheral blood leukocytes (PBL) using a highly sensitive PCR test and tryptase genotyping by digital droplet PCR. We also included 183 control individuals with large local reactions (LLRs) to Hymenoptera stings and with asymptomatic sensitization to Hymenoptera venoms.

Results

285 of 1319 individuals recommended for VIT (21.6%) were positive for KIT p.D816V in PBL, preferably those who present with severe reaction (33.9% [ n = 207 of 610] with Ring‐Messmer grade 3–4 vs. 11% [ n = 78 of 709] with Grade 1–2; p < .0001), whereas only 1.3% ( n = 2 of 152) of controls with LLR and none with asymptomatic sensitization ( n = 31) had KIT p.D816V. KIT p.D816V allelic burden was higher in those with severe reaction (median 0.018% [ n = 207] in Grade 3–4 vs. 0.001% [ n = 78] in Grade 1–2; p < .0001), and the majority had normal baseline serum tryptase levels (69% [ n = 196 of 285]). All KIT p.D816V‐positive individuals ( n = 41) who underwent bone marrow (BM) biopsy were found to have underlying clonal diseases, principally BM mastocytosis. HαT was also associated with severe HVA and symptoms ( p < .01), and remarkably, 31.0% ( n = 31 of 100) were found to have concomitant KIT p.D816V. Concomitant HαT and KIT p.D816V showed an additive effect, and having both was associated with the highest risk for severe HVA, even higher than having either HαT or KIT p.D816V alone (OR = 3.8; p < .01).

Conclusions

By employing prospective universal tryptase genotyping and examination for KIT p.D816V in PBL in large HVA populations, we have demonstrated a high burden of clonal MC disorders and HαT in patients who require VIT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthropod VenomsTryptasesHymenopteraDesensitization, ImmunologicHumansMaleFemaleAdultMiddle AgedAnimalsMastocytosisYoung AdultAdolescentMast CellsProto-Oncogene Proteins c-kitAgedChildInsect Bites and StingsHypersensitivityGenotypeChild, Preschool

Stichwörter der Autor:innen

anaphylaxishereditary α‐tryptasemiahypersensitivityimmunotherapymast cellmastocytosisvenom

Substanzen

Arthropod VenomsTryptasesProto-Oncogene Proteins c-kit

Autor:innen und Institutionen

  • University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.
  • Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
  • Faculty of Medicine, University of Maribor, Maribor, Slovenia.
  • Department of Dermatology and Venerology, Medical University of Graz, Graz, Austria.
  • Allergy Outpatient Clinic Reumannplatz, Vienna, Austria.
  • Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

ORCID-Profile: Peter Korošec, Gunter J Sturm, Mitja Košnik, Lisa Arzt-Gradwohl, Grzegorz Porebski, Matija Rijavec

Förderung

  • Javna Agencija za Raziskovalno Dejavnost RS
  • Division of Intramural Research, National Institute of Allergy and Infectious Diseases
  • Austrian Science Fund
  • NIAID NIH HHS

Zitieren

APA

Korošec, P., Sturm, G. J., Lyons, J. J., Marolt, T. P., Svetina, M., Košnik, M., Zidarn, M., Kačar, M., Frelih, N., Lalek, N., Luzar, A. D., Zver, S., Škerget, M., Czarnobilska, E., Dyga, W., Grle, S. P., Samarzija, M., Arzt-Gradwohl, L., Čerpes, U., …, & Rijavec, M. (2024). High burden of clonal mast cell disorders and hereditary α‐tryptasemia in patients who need Hymenoptera venom immunotherapy. Allergy. https://doi.org/10.1111/all.16084

Vancouver

Korošec P, Sturm GJ, Lyons JJ, Marolt TP, Svetina M, Košnik M, et al. High burden of clonal mast cell disorders and hereditary α‐tryptasemia in patients who need Hymenoptera venom immunotherapy. Allergy. 2024. doi:10.1111/all.16084

BibTeX
@article{Koroec2024,
  author = {Korošec, Peter and Sturm, Gunter J and Lyons, Jonathan J and Marolt, Tinkara Pirc and Svetina, Manca and Košnik, Mitja and Zidarn, Mihaela and Kačar, Mark and Frelih, Nina and Lalek, Nika and Luzar, Ajda Demšar and Zver, Samo and Škerget, Matevž and Czarnobilska, Ewa and Dyga, Wojciech and Grle, Sanja Popović and Samarzija, Miroslav and Arzt-Gradwohl, Lisa and Čerpes, Urban and Porebski, Grzegorz and Pevec, Branko and Schadelbauer, Eva and Kopač, Peter and Šelb, Julij and Rijavec, Matija},
  title = {High burden of clonal mast cell disorders and hereditary α‐tryptasemia in patients who need Hymenoptera venom immunotherapy},
  journal = {Allergy},
  year = {2024},
  doi = {10.1111/all.16084}
}
Kostenlos starten →